Monarch Capital Management Inc. bought a new stake in Becton Dickinson and Co (NYSE:BDX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 976 shares of the medical instruments supplier’s stock, valued at approximately $255,000.
Other hedge funds have also recently made changes to their positions in the company. Acropolis Investment Management LLC acquired a new position in Becton Dickinson and in the 3rd quarter valued at about $101,000. Almanack Investment Partners LLC. acquired a new position in Becton Dickinson and in the 2nd quarter valued at about $105,000. Truvestments Capital LLC acquired a new position in Becton Dickinson and in the 3rd quarter valued at about $105,000. Bridgeworth LLC acquired a new position in Becton Dickinson and in the 2nd quarter valued at about $131,000. Finally, Sageworth Trust Co acquired a new position in Becton Dickinson and in the 3rd quarter valued at about $147,000. 85.19% of the stock is owned by hedge funds and other institutional investors.
Shares of NYSE BDX traded down $5.70 on Thursday, reaching $239.22. 20,529 shares of the company traded hands, compared to its average volume of 1,139,136. Becton Dickinson and Co has a fifty-two week low of $209.91 and a fifty-two week high of $265.87. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.03 and a quick ratio of 0.69. The company has a market cap of $65.70 billion, a P/E ratio of 21.68, a P/E/G ratio of 1.69 and a beta of 1.21.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported $2.93 EPS for the quarter, meeting the Zacks’ consensus estimate of $2.93. Becton Dickinson and had a net margin of 1.47% and a return on equity of 13.88%. The company had revenue of $4.40 billion during the quarter, compared to the consensus estimate of $4.36 billion. During the same quarter in the prior year, the company posted $2.40 EPS. The company’s quarterly revenue was up 39.0% compared to the same quarter last year. As a group, equities research analysts anticipate that Becton Dickinson and Co will post 12.1 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 31st. Stockholders of record on Monday, December 10th will be paid a dividend of $0.77 per share. The ex-dividend date is Friday, December 7th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.29%. This is an increase from Becton Dickinson and’s previous quarterly dividend of $0.75. Becton Dickinson and’s dividend payout ratio is currently 27.25%.
In other news, EVP James W. Borzi sold 5,887 shares of the business’s stock in a transaction dated Friday, November 30th. The stock was sold at an average price of $252.37, for a total transaction of $1,485,702.19. Following the completion of the sale, the executive vice president now owns 6,013 shares in the company, valued at approximately $1,517,500.81. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Charles R. Bodner sold 2,080 shares of the business’s stock in a transaction dated Friday, November 16th. The stock was sold at an average price of $245.83, for a total value of $511,326.40. Following the sale, the senior vice president now owns 4,497 shares of the company’s stock, valued at approximately $1,105,497.51. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 81,795 shares of company stock valued at $19,571,318. Corporate insiders own 1.00% of the company’s stock.
Several research analysts recently weighed in on the stock. Morgan Stanley boosted their target price on shares of Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a research note on Thursday, October 4th. Wells Fargo & Co boosted their target price on shares of Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a research note on Thursday, September 6th. They noted that the move was a valuation call. Citigroup boosted their target price on shares of Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a research note on Wednesday, August 8th. UBS Group started coverage on shares of Becton Dickinson and in a research note on Tuesday, November 27th. They issued a “neutral” rating and a $260.00 target price for the company. Finally, Piper Jaffray Companies dropped their price objective on shares of Becton Dickinson and to $250.00 and set an “overweight” rating for the company in a research note on Tuesday, November 6th. Six investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $254.20.
TRADEMARK VIOLATION NOTICE: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/12/06/monarch-capital-management-inc-invests-255000-in-becton-dickinson-and-co-bdx-stock.html.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Recommended Story: What is intrinsic value?
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.